JAK1

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Retrieved on: 
Thursday, January 19, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Janus, Disease, Sun Pharma, BSE, NSE, Autoimmune disease, R, CNCE, JAK1, CVR, Depression, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dermatology, Safety, Deuterium, FDA, Hair loss, NDA, Woman, Immune system, Scalp, Food, Patient, CVR Partners, JAK2, Sale, Acquisition, Multimedia, Janus kinase, Reuters, Alopecia areata, Life, Investment, Concert, Hair, Wardwell, Security (finance), Pharmaceutical industry, Ophthalmology

Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development.

Key Points: 
  • Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development.
  • Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime1,2,3.
  • The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib,” said Abhay Gandhi, CEO North America, Sun Pharma.
  • “There is a significant unmet need in the Alopecia Areata space and we aim to build on Concert’s commitment to supporting the Alopecia Areata patient community.

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, December 20, 2022
CTI, Vera, Patient, Platelet, Employment, CTIC, Financial compensation, JAK2, FDA, Thrombocytopenia, Galena Biopharma, Ruxolitinib, JAK1, Acquisition, Pharmaceutical industry, Amend

The equity awards were approved on December 20, 2022, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved on December 20, 2022, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received options to purchase an aggregate of 33,000 shares of CTI BioPharma common stock.
  • One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates.
  • VONJO® is a registered trademark of CTI BioPharma Corp.

Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255

Retrieved on: 
Monday, December 5, 2022
Dermatitis, Janus kinase 1, Hair loss, Trial of the century, Inflammation, Atopic dermatitis, FDA, Safety, 2009 Davis Cup, Hair follicle, Skin, Pharmacokinetics, Hair, Recurrence, Dermatology, Face, Form 10-K, Alopecia areata, Risk, JAK1, Immune system, Scalp, Volunteering, Patient, Pharmaceutical industry

“Alopecia areata is an immune condition that not only causes hair loss, but also causes significant negative impact on an individual’s emotional and mental wellbeing.

Key Points: 
  • “Alopecia areata is an immune condition that not only causes hair loss, but also causes significant negative impact on an individual’s emotional and mental wellbeing.
  • Today, there are no FDA-approved topical therapies to treat the condition,” said Frank Watanabe, President and CEO at Arcutis.
  • ARQ-255, or topical invarmactiniib suspension, is a topical janus kinase 1 (JAK1) inhibitor therapy for alopecia areata.
  • Topical treatment of alopecia areata is challenging due to the depth of inflammation and the dense vasculature that surrounds the hair bulb.

New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients

Retrieved on: 
Sunday, December 11, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Janus, Thrombocytopenia, JAK1, Food, Weakness, Genta (company), Danazol, Primary myelofibrosis, Diagnosis, EMA, Patient, JAK, Anemia, Splenomegaly, Annual report, Ruxolitinib, Fatigue, Disease, FDA, ACVR1, Quality of life, Momelotinib, US Foods, European Medicines Agency, COVID-19, Survival, Antibody, JAK2, Marketing, Bone marrow, Clinical trial, Safety, GSK, Symptoms of COVID-19, Inhibitor, ASH, TI, Pharmaceutical industry, Medical imaging

Additionally, these efficacy and safety results in patients with thrombocytopenia were consistent with the overall population.

Key Points: 
  • Additionally, these efficacy and safety results in patients with thrombocytopenia were consistent with the overall population.
  • An additional analysis from the MOMENTUM clinical trial evaluated the impact of TI response on overall survival (abstract #3028).
  • As previously presented, patients receiving treatment with momelotinib were more likely to achieve transfusion independence during the study period than patients treated with danazol (TI response at week 24 of 31% and 20% for the momelotinib and danazol arms, respectively; non-inferiority p=0.0064).
  • Momelotinib patients were also less likely to require a transfusion during the study period (35% of momelotinib patients had zero units transfused compared to 17% of danazol patients; odds ratio=2.7; p=0.0107), and more likely to reduce transfusion burden.

CTI BioPharma to Present at the JMP Securities Hematology and Oncology Summit

Retrieved on: 
Wednesday, November 30, 2022
Ruxolitinib, JAK2, JAK1, Acquisition, Patient, Hematology, CTI, CTIC, Vera, Platelet, Thrombocytopenia, FDA, Pharmaceutical industry

SEATTLE, Nov. 30, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit at 3:00 p.m.

Key Points: 
  • SEATTLE, Nov. 30, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit at 3:00 p.m.
  • CTI has one FDA-approved product, VONJO (pacritinib), a JAK2 and IRAK1 inhibitor, that spares JAK1.
  • CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
  • VONJO is a registered trademark of CTI BioPharma Corp.

Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 8, 2022
Janus, GLOBE, AstraZeneca, JAMA, Investigational New Drug, Intellectual property, IND, Journal of the European Academy of Dermatology and Venereology, Director, Skin, Shanda, FDA, Nasdaq, Webcast, New Drug Application, PDE4, Completeness, PAP, U.S. Securities and Exchange Commission, Board, G&A, R, Atopic dermatitis, SEC, American Medical Association, Board of directors, Company, Dermatitis, Clinical trial, Journal, Research, Vitiligo, Psoriasis, Patient, Physician, Growth, Awareness, Pharmacy, Scalp, Acquisition, NDA, JAK1, Ageing, Congress, Fine chemical, Pharmaceutical industry, Cosmetics, Medical device, Venereology, Facebook, Dermatology

Effective November 2022, ZORYVE is now covered by one of the top pharmacy benefit managers and a large national health plan.

Key Points: 
  • Effective November 2022, ZORYVE is now covered by one of the top pharmacy benefit managers and a large national health plan.
  • In September 2022, Arcutis announced positive topline results from the ARRECTOR pivotal Phase 3 trial for the treatment of scalp and body psoriasis.
  • Ms. Krishnamohan brings a depth of business, financial and investment experience, including deep knowledge of Arcutis' business having previously worked on the Company's initial public offering.
  • Arcutis management will host a conference call and webcast today at 5:00pm ET to discuss the financial results for the quarter and provide a business update.

CTI BioPharma to Present at Upcoming November Conferences

Retrieved on: 
Tuesday, November 8, 2022
Acquisition, NASDAQ, Patient, FDA, Platelet, JAK1, JAK2, Vera, Ruxolitinib, Thrombocytopenia, CTI, CTIC, Pharmaceutical industry

SEATTLE, Nov. 8, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in New York and London.

Key Points: 
  • SEATTLE, Nov. 8, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in New York and London.
  • CTI has one FDA-approved product, VONJO (pacritinib), a JAK2 and IRAK1 inhibitor, that spares JAK1.
  • CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
  • VONJO is a registered trademark of CTI BioPharma Corp.

CTI BioPharma Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 7, 2022
Janus, Society, Ruxolitinib, Nasdaq, Pacritinib, Thrombocytopenia, Platelet, Data analysis, Annual general meeting, Operating cost, Bleeding, ID, Investment, Myeloproliferative neoplasm, ASH, Hematology-Oncology and Stem Cell Transplantation Research Center, Primary myelofibrosis, Vera, CTI, Growth, Galena Biopharma, FLT3, ALK2, Webcast, JAK2, Anemia, CTIC, Patient, Mastocytosis, Telephone, JAK1, BID, Haematopoiesis, SOHO, Safety, Syndrome, Cytokine, FDA, Pharmaceutical industry, ACVR1

SEATTLE, Nov. 7, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter ended September 30, 2022.

Key Points: 
  • ET
    SEATTLE, Nov. 7, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter ended September 30, 2022.
  • "In the third quarter, CTI continued to make strong progress with the U.S. commercial launch of VONJO, delivering net revenue of $18.2 million, a 48% increase in sales compared to the second quarter.
  • CTI will host a conference call and webcast to review its third quarter 2022 financial results and provide an update on business activities today, November 7, 2022, at 4:30 p.m.
  • "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions.

Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

Retrieved on: 
Friday, November 4, 2022
UC, CPK, Kidney disease, Lipid, Investigational New Drug, Investment, Saitama (city), Board, BCMA, FDA, D, CD, Safety, IND, Interferon, Fibrosis, SLE, Quality of life, CD19, RA, Intention, Rheumatoid arthritis, EULAR, Inflammatory bowel disease, CET, CEO, Filgotinib, JAK1, Gilead Sciences, Ulcerative colitis, NASDAQ, Jaki, Galapagos NV, Rheumatism, Union, Euronext, Psoriasis, Axial spondyloarthritis, Kidney, TYK2, JAK2, Patient, Renewable energy, Fine chemical, Pharmaceutical industry, Medical imaging, Vaccine, Dermatomyositis

Our renewed focus on two strategic therapeutic areas goes hand in hand with redirecting our resources.

Key Points: 
  • Our renewed focus on two strategic therapeutic areas goes hand in hand with redirecting our resources.
  • Aligned with our Vision 2028, we presented our financial outlook and capital allocation strategy at our R&D Day 2022.
  • We also presented our Vision 2028 roadmap for oncology at our R&D Day 2022.
  • Our first medicine for rheumatoid arthritis and ulcerative colitis is available in the European Union, Norway, Great Britain, and Japan.

CTI BioPharma Announces Oral Presentation at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition

Retrieved on: 
Thursday, November 3, 2022
Janus, FDA, CTIC, FLT3, JAK2, Vera, Syndrome, ALK2, Ruxolitinib, JAK1, Society, Haematopoiesis, Patient, Company, ASH, Exposition, Primary myelofibrosis, Pacritinib, Myeloproliferative neoplasm, Acquisition, Mastocytosis, Platelet, Cytokine, Thrombocytopenia, Nasdaq, CTI, Pharmaceutical industry

SEATTLE, Nov. 3, 2022 /PRNewswire/ --CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation and two poster presentations from the Company's pacritinib program at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in New Orleans, Louisiana and virtually December 10-13, 2022.

Key Points: 
  • SEATTLE, Nov. 3, 2022 /PRNewswire/ --CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation and two poster presentations from the Company's pacritinib program at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in New Orleans, Louisiana and virtually December 10-13, 2022.
  • The details of the oral presentation are as follows:
    Session Name: 634.
  • Myeloproliferative Syndromes: Clinical and Epidemiological: Towards Personalized Medicine in Myeloproliferative Neoplasms and Mastocytosis: New and Repurposed Drugs for Unmet Clinical Needs
    The details of the poster presentations are as follows:
    Session Name: 631.
  • VONJO is a registered trademark of CTI BioPharma Corp.